Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triptorelin for HIV-1 reservoir reduction in men on suppressive ART
2017-004160-35Phase 2Active
- Sponsor
- ISR Immune System Regulation
- Start
- Dec 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of triptorelin in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ISR Immune System Regulation. Primary endpoint: Change in total HIV-1 DNA in CD4+ cells at week 12. Started Dec 2017; status: active.
02
Drugs
triptorelin
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-004160-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004160-35.